213 related articles for article (PubMed ID: 11367559)
1. HIV-1 integrase: the next target for AIDS therapy?
d'Angelo J; Mouscadet JF; Desmaële D; Zouhiri F; Leh H
Pathol Biol (Paris); 2001 Apr; 49(3):237-46. PubMed ID: 11367559
[TBL] [Abstract][Full Text] [Related]
2. Active site binding modes of curcumin in HIV-1 protease and integrase.
Vajragupta O; Boonchoong P; Morris GM; Olson AJ
Bioorg Med Chem Lett; 2005 Jul; 15(14):3364-8. PubMed ID: 15950462
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of HIV-1 integrase inhibitors--enzyme-ligand interactions.
Maurin C; Bailly F; Cotelle P
Curr Med Chem; 2003 Sep; 10(18):1795-810. PubMed ID: 12871105
[TBL] [Abstract][Full Text] [Related]
4. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
Garvey EP; Johns BA; Gartland MJ; Foster SA; Miller WH; Ferris RG; Hazen RJ; Underwood MR; Boros EE; Thompson JB; Weatherhead JG; Koble CS; Allen SH; Schaller LT; Sherrill RG; Yoshinaga T; Kobayashi M; Wakasa-Morimoto C; Miki S; Nakahara K; Noshi T; Sato A; Fujiwara T
Antimicrob Agents Chemother; 2008 Mar; 52(3):901-8. PubMed ID: 18160521
[TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics studies of the wild-type and double mutant HIV-1 integrase complexed with the 5CITEP inhibitor: mechanism for inhibition and drug resistance.
Barreca ML; Lee KW; Chimirri A; Briggs JM
Biophys J; 2003 Mar; 84(3):1450-63. PubMed ID: 12609852
[TBL] [Abstract][Full Text] [Related]
6. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells.
Mekouar K; Mouscadet JF; Desmaële D; Subra F; Leh H; Savouré D; Auclair C; d'Angelo J
J Med Chem; 1998 Jul; 41(15):2846-57. PubMed ID: 9667973
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the interaction of HIV-1 integrase and its dicaffeoylquinic acid inhibitor through molecular modeling approach.
Hu Z; Chen D; Dong L; Southerland WM
Ethn Dis; 2010; 20(1 Suppl 1):S1-45-9. PubMed ID: 20521384
[TBL] [Abstract][Full Text] [Related]
8. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.
McColl DJ; Chen X
Antiviral Res; 2010 Jan; 85(1):101-18. PubMed ID: 19925830
[TBL] [Abstract][Full Text] [Related]
9. Structure-based virtual screening toward the discovery of novel inhibitors for impeding the protein-protein interaction between HIV-1 integrase and human lens epithelium-derived growth factor (LEDGF/p75).
Panwar U; Singh SK
J Biomol Struct Dyn; 2018 Sep; 36(12):3199-3217. PubMed ID: 28948865
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 integrase and RNase H activities as therapeutic targets.
Andréola ML; De Soultrait VR; Fournier M; Parissi V; Desjobert C; Litvak S
Expert Opin Ther Targets; 2002 Aug; 6(4):433-46. PubMed ID: 12223059
[TBL] [Abstract][Full Text] [Related]
11. Mining the NCI antiviral compounds for HIV-1 integrase inhibitors.
Deng J; Kelley JA; Barchi JJ; Sanchez T; Dayam R; Pommier Y; Neamati N
Bioorg Med Chem; 2006 Jun; 14(11):3785-92. PubMed ID: 16460953
[TBL] [Abstract][Full Text] [Related]
12. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase.
Robinson WE; Cordeiro M; Abdel-Malek S; Jia Q; Chow SA; Reinecke MG; Mitchell WM
Mol Pharmacol; 1996 Oct; 50(4):846-55. PubMed ID: 8863829
[TBL] [Abstract][Full Text] [Related]
13. Structure and function of HIV-1 integrase.
Chiu TK; Davies DR
Curr Top Med Chem; 2004; 4(9):965-77. PubMed ID: 15134551
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 integrase: a target for new AIDS chemotherapeutics.
Anthony NJ
Curr Top Med Chem; 2004; 4(9):979-90. PubMed ID: 15134552
[TBL] [Abstract][Full Text] [Related]
15. HIV type 1 integrase inhibitors: from basic research to clinical implications.
Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture.
Zouhiri F; Mouscadet JF; Mekouar K; Desmaële D; Savouré D; Leh H; Subra F; Le Bret M; Auclair C; d'Angelo J
J Med Chem; 2000 Apr; 43(8):1533-40. PubMed ID: 10780910
[TBL] [Abstract][Full Text] [Related]
17. Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore.
Hong H; Neamati N; Winslow HE; Christensen JL; Orr A; Pommier Y; Milne GW
Antivir Chem Chemother; 1998 Nov; 9(6):461-72. PubMed ID: 9865384
[TBL] [Abstract][Full Text] [Related]
18. Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design.
Karki RG; Tang Y; Burke TR; Nicklaus MC
J Comput Aided Mol Des; 2004 Dec; 18(12):739-60. PubMed ID: 16075307
[TBL] [Abstract][Full Text] [Related]
19. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes.
Grobler JA; Stillmock K; Hu B; Witmer M; Felock P; Espeseth AS; Wolfe A; Egbertson M; Bourgeois M; Melamed J; Wai JS; Young S; Vacca J; Hazuda DJ
Proc Natl Acad Sci U S A; 2002 May; 99(10):6661-6. PubMed ID: 11997448
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HIV-1 integrase by small molecules: the potential for a new class of AIDS chemotherapeutics.
Young SD
Curr Opin Drug Discov Devel; 2001 Jul; 4(4):402-10. PubMed ID: 11727305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
